Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$76.28 USD

76.28
6,661,532

-0.79 (-1.03%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $76.29 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

by Zacks Equity Research

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

Zacks Equity Research

Novo Nordisk (NVO) to Expand Manufacturing Site in France

by Zacks Equity Research

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Zacks Equity Research

Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Here's Why Astrazeneca (AZN) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

by Zacks Equity Research

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use

by Kinjel Shah

FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication

Zacks Equity Research

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

by Zacks Equity Research

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

Zacks Equity Research

Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise

by Zacks Equity Research

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

Zacks Equity Research

Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

by Zacks Equity Research

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Zacks Equity Research

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

by Zacks Equity Research

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

Zacks Equity Research

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

by Zacks Equity Research

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.

Zacks Equity Research

Jobless Claims Decreased More Than Expected

by Zacks Equity Research

Jobless Claims Decreased More Than Expected

Mark Vickery headshot

Pre-Markets Strong on Higher Bond Rates, Mixed Earnings

by Mark Vickery

While this positive sentiment is welcome, we note bond yield rates going higher this morning.

Zacks Equity Research

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.

Zacks Equity Research

Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Zacks Equity Research

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.

Zacks Equity Research

Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.

Zacks Equity Research

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Zacks Equity Research

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.